The content on this site is intended for healthcare professionals only
Xevinapant plus standard of care chemoradiotherapy improved 5 year OS for unrese...
Prof Jean Bourhis - University Hospital of Lausanne, Lausanne, Switzerland
27 Sep 2022
Intraoperative Radiotherapy
Dr Mahima Pant - National Academy for Medical Sciences (NAMS), Kathmandu, Nepal
25 Sep 2022
Cancer survivors' stories: An African perspective
Dr Zainab Shinkafi-Bagudu - Founder of the Medicaid Cancer Foundation
15 Sep 2022
Pembrolizumab/carboplatin/paclitaxel combo shows antitumour activity in first-li...
Dr Marcin Dzienis - Gold Coast University Hospital, Southport, Australia
14 Sep 2022
ESMO 2022: Highlights, commentary and analysis
Dr Bishal Gyawali - Queen's University, Kingston, Canada
12 Sep 2022
A new era of early cancer detection with blood test may change cancer screening ...
Dr Deb Schrag, Memorial Sloan Kettering Cancer Center, New York, USA
11 Sep 2022
Pembrolizumab with chemoradiation therapy vs placebo plus CRT for locally advanc...
Prof Jean-Pascal Machiels - Cliniques Universitaires Sain-Luc, Brussels, Belgium
11 Sep 2022
Pembro + CRT in HNSCC fails to deliver statistically significant event-free surv...
Prof Jean-Pascal Machiels - Cliniques Universitaires Sain-Luc, Brussels, Belgium
11 Sep 2022
New era of early cancer detection blood tests on the horizon
Dr Deborah Schrag - Memorial Sloan Kettering Cancer Center, New York City, USA
11 Sep 2022
Prognostic model of all-cause mortality at 30 days in patients with cancer and C...
Dr Chris Labaki - Dana-Farber Cancer Institute, Boston, USA
11 Sep 2022
New data presented at ESMO for multi-cancer early detection
Dr Tom Beer - Vice President and Chief Medical Officer of Exact Sciences
10 Sep 2022
Working to improve global cancer care access in low middle-income countries
Dr Julie Gralow, Prof Eduardo Cazap
25 Jul 2022